Aarti Pharmalabs Ltd

Revenue from operations fell 8.66% YoY to Rs 418.33 crore in the quarter ended 30 September 2025. Profit before tax (PBT) stood at Rs 38.69 crore in Q2 FY26, down 46.09% from Rs 71.77 crore in the same period last year. Total expenses decreased 2.99% to Rs 379.05 crore in Q2 FY26, compared to Rs 379.05 crore in Q2 FY26. The cost of materials consumed stood at Rs 203.46 crore (down 4.91% YoY), employee benefit expenses were Rs 43.41 crore (up 15.05% YoY) and finance costs stood at Rs 10.67 crore (up 93.64% YoY) during the period under review. On half-year basis, the company's consolidated net profit climbed 29.64% to Rs 77.45 crore on 20.62% decrease in revenue to Rs 804.53 crore in H1 FY26 over H1 FY25. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. Powered by Capital Market - Live

Net profit of Aarti Pharmalabs declined 48.88% to Rs 27.92 crore in the quarter ended September 2025 as against Rs 54.62 crore during the previous quarter ended September 2024. Sales declined 8.67% to Rs 418.33 crore in the quarter ended September 2025 as against Rs 458.03 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales418.33458.03 -9 OPM %17.7120.45 - PBDT63.4692.65 -32 PBT38.6971.77 -46 NP27.9254.62 -49 Powered by Capital Market - Live

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 9 November 2025.Powered by Capital Market - Live

According to an exchange filing, the company confirmed that it has received all necessary approvals and permissions to commence operations at the site. Phase 1 includes a total reactor capacity of 440 kilolitres (kL), with 63 reactors. The greenfield facility spans 80 acres and is designed for significant scalability, with potential to expand capacity up to 8'10 times that of Phase 1 in the future. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. The company reported a 10.73% decline in consolidated net profit to Rs 49.50 crore in Q1 FY26, compared to Rs 55.45 crore posted in Q1 FY25. Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025. Powered by Capital Market - Live

Aarti Pharmalabs announced that the Annual General Meeting(AGM) of the company will be held on 22 September 2025.Powered by Capital Market - Live

Aarti Pharmalabs has fixed 15 September 2025 as record date for payment of final dividend for the financial year 2024-25. The dividend will be paid on or before 20 October 2025.Powered by Capital Market - Live

Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025. Profit before tax (PBT) stood at Rs 65.45 crore in Q1 FY26, down 11.16% from Rs 73.68 crore in the same period last year. Total expenses fell 33.77% to Rs 320.54 crore in Q1 FY26, compared to Rs 484.03 crore in Q1 FY25. The cost of materials consumed stood at Rs 191.42 crore (down 8.05% YoY), employee benefit expenses were Rs 41.26 crore (up 5.17% YoY), and finance costs stood at Rs 6.79 crore (up 40.57% YoY) during the period under review. EBITDA declined 1.24% YoY to Rs 95.30 crore in Q1 FY26. However, the EBITDA margin improved to 24.68% in Q1 FY26, up from 17.37% in Q1 FY25. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India. Powered by Capital Market - Live

Net profit of Aarti Pharmalabs declined 10.73% to Rs 49.50 crore in the quarter ended June 2025 as against Rs 55.45 crore during the previous quarter ended June 2024. Sales declined 30.48% to Rs 386.19 crore in the quarter ended June 2025 as against Rs 555.49 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales386.19555.49 -30 OPM %24.2017.36 - PBDT88.2593.84 -6 PBT65.4573.68 -11 NP49.5055.45 -11 Powered by Capital Market - Live

Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live

Revenue from operations jumped 11.46% YoY to Rs 563.78 crore in in the quarter ended 31 March 2025. Profit before tax was at Rs 114.62 crore in the fourth quarter of FY25, up 19.70% from Rs 95.75 crore posted in the same period a year ago. Total expenses increased 8.61% to Rs 447.55 crore in Q4 FY25, compared to Rs 412.05 crore reported in Q4 FY24. The cost of material consumed stood at Rs 185.45 crore (down 7.97% YoY), employee benefit expenses were at Rs 43.37 crore (up 43.37% YoY) and finance costs stood at Rs 6.58 crore (up 40.59% YoY) during the period under review. On a full-year basis, the company's net profit rose 25.58% to Rs 272.40 crore on a 14.16% increase in revenue to Rs 2,115.07 crore in FY25 over FY24. The company's board has recommended a dividend of Rs 2.5 per equity share for the financial year 2024-25. Subject to the approval of the shareholders at the ensuing annual general meeting of the company. Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The counter declined 1.33% to Rs 757.15 on the BSE. Powered by Capital Market - Live